Header Image

Investor Relations

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27
RESEARCH TRIANGLE PARK, N.C. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its fourth quarter and full year 2017 financial results will be reported on Tuesday, February 27, 2018 . BioCryst will host a conference call and webcast at 11:00 a.m.
View HTML
Toggle Summary BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences View HTML
Toggle Summary BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients With Rare Diseases View HTML
Toggle Summary BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
Novel approach using ALK2 inhibition RESEARCH TRIANGLE PARK, N.C. , Jan. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it has advanced a program exploring activin receptor-like kinase-2 (ALK2) inhibitors for treatment of Fibrodysplasia Ossificans
View HTML
Toggle Summary BioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK,  N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 36 th annual J.P.
View HTML
Toggle Summary BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the 29 th Annual Piper Jaffray
View HTML
Toggle Summary BioCryst Reports Third Quarter 2017 Financial Results
BCX7353 Phase 3 program agreed with FDA and EMA U.S. Orphan Drug designation for BCX7353 received from FDA RESEARCH TRIANGLE PARK, N.C. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the third quarter ended September 30, 2017 .
View HTML
Toggle Summary BioCryst to Present at the Jefferies 2017 London Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Jefferies 2017 London Healthcare
View HTML
Toggle Summary BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI's 2017 Annual Scientific Meeting
RESEARCH TRIANGLE PARK, N.C. , Oct. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that results from its successful Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE) will be presented at the American College of Allergy, Asthma & Immunology
View HTML
Toggle Summary BioCryst to Announce Third Quarter 2017 Financial Results on November 7
RESEARCH TRIANGLE PARK, N.C. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its third quarter 2017 financial results will be reported on Tuesday, November 7, 2017 . BioCryst will host a conference call and webcast at 11:00 a.m.
View HTML